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Background
In the SIV/macaque model of HIV in man, live attenuated
virus confers the most potent protection against wild-type
virus challenge. We have developed a novel live attenu-
ated (nef deleted) vaccine SIVmac239 (SIVrtTA) that is
dependent on doxycycline for replication in vivo. With-
drawal of doxycycline prevents replication of SIVrtTA. We
used this virus to vaccinate rhesus macaques to investigate
the role of virus replication and persistence in protection
against SIVmac239 challenge.
Methods
Two groups of 6 rhesus macaques were vaccinated with
SIVrtTA and simultaneously dosed orally with doxycy-
cline for 6 months. In one group (A) the dosing was
stopped 8 weeks before challenge with SIVmac239 whilst
in the other group dosing was maintained. A further con-
trol group (C) was vaccinated with attenuated
SIVmac239Δnef with doxycycline dosing for 6 months
and challenged with SIVmac239 along with a naive group
(D) of 4 animals.
Results
Upon inoculation with the conditional replicating SIV, all
animals became infected. Virus was recovered from blood
and sequence analysis determined that there was no
escape by the virus from antibiotic dependence. Virus
RNA levels were determined from blood and followed a
similar profile to other live attenuated SIV (with peak
loads of 3–4 log titres at day 14 followed by a gradual
decline). Two weeks following challenge with SIVmac239,
plasma viral RNA levels were undetectable in one animal
of group A. The other animals in both groups (A and B)
vaccinated with SIVrtTA showed reduced RNA levels
(range 2–6 log titres) compared to those (~7 log titre) of
the naive control group (D). Three of the four group C
animals vaccinated with SIVmac239Δnef were protected.
Conclusion
Inoculation with SIVrtTA showed a marked vaccine effect.
This new live attenuated virus will be a useful tool to iden-
tify the correlates of protection by this vaccine strategy.
from AIDS Vaccine 2009
Paris, France. 19–22 October 2009
Published: 22 October 2009
Retrovirology 2009, 6(Suppl 3):P25 doi:10.1186/1742-4690-6-S3-P25
<supplement> <title> <p>AIDS Vaccine 2009</p> </title> <editor>Anna Laura Ross</editor> <note>Meeting abstracts – A single PDF containing all abstracts in this Supplement is available <a href="http://www.biomedcentral.com/content/files/pdf/1742-4690-6-S3-full.pdf">here</a>.</note> <url>http://www.biomedcentral.com/content/pdf/1471-2105-10-S12-info.pdf</url> </supplement>
This abstract is available from: http://www.retrovirology.com/content/6/S3/P25
© 2009 Page et al; licensee BioMed Central Ltd. 
